BRAF
7 drugsB-Raf Proto-Oncogene
Predictive biomarker for patient selection in 16 indications
Understanding BRAF
What it means: BRAF is a serine/threonine kinase in the MAPK signaling pathway. Mutations (most commonly V600E) cause constitutive activation.
Why it matters: BRAF inhibitors (vemurafenib, dabrafenib) combined with MEK inhibitors show strong responses in BRAF-mutant cancers.
Testing: Tested via NGS, PCR-based assays, or IHC (V600E-specific antibody). NGS detects all BRAF variants.
7
Approved Drugs
16
Indications
6
Companies
BRAF is a precision-medicine biomarker linked to 7 FDA-approved targeted drugs from 6 companies, spanning 16 indications including Metastatic colorectal cancer, Locally advanced, unresectable or metastatic gastrointestinal stromal tumor, Hepatocellular carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing BRAF drugs below.
Search BRAF Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting BRAF
BRAF Indications
Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Gastrointestinal Stromal Tumor Melanoma Non-Small Cell Lung Cancer Anaplastic Thyroid Cancer Solid Tumors Hepatocellular Carcinoma Renal Cell Carcinoma Thyroid Carcinoma Low-Grade Glioma Erdheim-Chester Disease Unresectable hepatocellular carcinoma Advanced renal cell carcinoma Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment